NasdaqGS · Biotechnology

Aardvark Therapeutics (AARD)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+112.6%

$14.50 average target

$6.82+0.93 (+15.8%)Latest market snapshot · Yahoo Finance

Market cap$149.3M

Cash$73.9M

Quarterly burn$18.9M

Pipeline assets2

Short float4.5%

Clinical portfolio

Aardvark Therapeutics Drug Pipeline

Showing 1 of 2

Asset	Indication	Stage	Milestone	Signals ?
ARD-101	Prader-Willi Syndrome	Phase 3	Sep 30, 2026	—

Continue with BioPharma ProUnlock 1 additional programs and complete development details.

Unlock Pro

Upcoming milestones

AARD Catalyst Timeline

1 currently tracked

Sep 30, 2026

ARD-101

Phase 3

Prader-Willi Syndrome

Data readout

Event details

Company profile

About Aardvark Therapeutics

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.